Culture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the companyFrom animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how Share XCulture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the companyhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/fujifilm-irvine-scientific-coo-cell-therapy-covid-vaccines/
LEO Pharma’s new R&D lead on driving agility in drug developmentAfter 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research Share XLEO Pharma’s new R&D lead on driving agility in drug developmenthttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/leo-pharma-rd-lead-agility-drug-development/
Solving the “information challenge” of rare disease diagnosisGetting a diagnosis is often the biggest challenge facing a rare disease patient in the UK. We take Share XSolving the “information challenge” of rare disease diagnosishttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/solving-the-information-challenge-of-rare-disease-diagnosis/
Digitalising drug discoveryThe oceans of health data out there can be overwhelming for pharma companies to manage – but if Share XDigitalising drug discoveryhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/digitalising-drug-discovery-data-ai/
Centessa’s founder on the new company’s unique R&D modelPutting together a quarter-billion dollar pharma company from ten mergers in four months is not for the faint-hearted Share XCentessa’s founder on the new company’s unique R&D modelhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/centessa-founder-companys-unique-rd-model/
The landscape for UK R&D SMEs post-COVIDBig pharma might have dominated COVID headlines with its vaccine drive, but behind the scenes an army of Share XThe landscape for UK R&D SMEs post-COVIDhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/the-landscape-for-uk-rd-smes-post-covid/
Inside the UK’s leading efforts to restart clinical researchA herculean national effort has seen 69% of paused studies due to COVID restarted under the National Institute Share XInside the UK’s leading efforts to restart clinical researchhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/inside-uks-leading-efforts-restart-clinical-research/
Focus on Rare: the invisible burden of rare diseasesEmma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living Share XFocus on Rare: the invisible burden of rare diseaseshttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/focus-on-rare-the-invisible-burden-of-rare-diseases/
The post-COVID face of pharma research and developmentThe acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & Share XThe post-COVID face of pharma research and developmenthttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/telemedicine-remote-site-visits-post-covid-pharma-rd/
